Geriatric Care for Older People Hospitalised for COVID-19 (COVAGERT)

Impact of Geriatric Care in the Treatment of Older People Hospitalised for COVID-19

Current COVID-19 pandemic implies regular treatment adaptation by physician, according to scientific publication evolution. Older adults are particularly affected by COVID-19, with the higher severe form prevalence and the higher mortality rate. Furthermore older peoples are at high risk of complications cascade, due to the SARS-Voc-2 infection but also because of chronic diseases decompensation. If risk factors in this population have been identified, specific treatments to reduce complications or to be curative are less known. However geriatric care, thanks to its holistic approach, could reduce these complications and improve survival.

Our study aims to determine if geriatric care provided in geriatric COVID-19 hospitalisation units improves survival of older people (aged 65 years and over) at one month in comparison with conventional COVID-19 hospitalisation unit during the first wave in the Montpellier University Hospital. Secondary objectives are to determine if clinical characteristics of older patients are different between conventional and geriatric COVID-19 hospitalisation units, to assess influence of clinical characteristics of older patients on their survival, and to determine wich treatment have been delivered for older people during the COVID-19 pandemic first wave in our hospital in view of bibliographic data available at this time.

COVAGERT is a monocentric, descriptive, observational and retrospective study, including all older adults aged 65 years and over hospitalised in the geriatric COVID-19 and the conventional COVID-19 units of the Montpellier University Hospital during the first wave of the SARS-Cov-2 pandemic (between March 1th 2020 and September 1th 2020). Principal outcome is the survival one months after the RT-PCR positive test. Some data about treatments, medical history, socio-demographic and clinical characteristics will be collected from the medical record.

Statistical analysis will be performed using univariate and multivariate regressions according to the study's objectives.

Results will be useful to determine the bring of geriatric care during the current pandemic, but also to highlight the importance of multidisciplinary assessment in this complex disease and for further emergency medical challenges.

Study Overview

• Status: Completed
• Conditions: Covid19

• Study Type: Observational
• Enrollment (Actual): 230

Contacts and Locations

Study Locations

• France
  • Montpellier, France, 34295
    • UHMontpellier

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 65 years and older (Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

Older adults aged 65 years and over, hospitalised in the conventional or the geriatric COVID-19 hospitalisation unit during the first COVID-19 wave in the Montpellier University Hospital

Description

Inclusion criteria:

• adult age 65 years or over
• hospitalised for COVID-19 in one of the two hospitalisation unit (conventional or geriatric) during the first COVID19 wave

Exclusion criteria:

- refusal to give the access to her/his medical record

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
survival one month after positive SARS Cov 2 RT-PCR test	survival one month after positive SARS Cov 2 RT-PCR test	day 1

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
number of delivered treatments	delivered treatments	day 1
type of clinical characteristics	type of clinical characteristics	day 1
type of socio-demographic characteristics	type of socio-demographic characteristics	day 1

Collaborators and Investigators

• Sponsor: University Hospital, Montpellier
• Investigators: Study Director: Miot stéphanie, PH, University Hospital, Montpellier

Study record dates

Study Major Dates

• Study Start (Actual): June 1, 2021
• Primary Completion (Actual): December 1, 2021
• Study Completion (Actual): December 30, 2021

Study Registration Dates

• First Submitted: June 30, 2021
• First Submitted That Met QC Criteria: June 30, 2021
• First Posted (Actual): July 1, 2021

Study Record Updates

• Last Update Posted (Actual): April 12, 2022
• Last Update Submitted That Met QC Criteria: April 11, 2022
• Last Verified: April 1, 2022

More Information

Terms related to this study

• Keywords: COVID-19; Older adults; Comprehensive geriatric assessment (CGA)
• Additional Relevant MeSH Terms: Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Virus Diseases; Infections; Respiratory Tract Infections; Respiratory Tract Diseases; Pneumonia, Viral; Pneumonia; Lung Diseases; COVID-19
• Other Study ID Numbers: RECHMPL21_0372

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED
• IPD Plan Description: NC

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No